Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations

Atherosclerosis imaging with 18F-FDG PET is useful for tracking inflammation within plaque and monitoring the response to drug therapy. Short-term reproducibility of this technique in peripheral artery disease has not been assessed, and the optimal method of 18F-FDG quantification is still debated. We imaged 20 patients with vascular disease using 18F-FDG PET twice, 14 d apart, and used these data to assess reproducibility measures and compare 2 methods of 18F-FDG uptake measurement. We also reviewed the literature on quantification methods to determine the optimal measures of arterial 18F-FDG uptake for future studies. Methods: Twenty patients with vascular disease underwent PET/CT of the iliac, femoral, and carotid arteries 90 min after 18F-FDG administration. In 19 patients, repeat testing was performed at 2 wk. Coregistration and attenuation correction were performed with CT. Vessel 18F-FDG uptake was measured as both the mean and maximum blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). We assessed interscan, interobserver, and intraobserver agreement. Results: Nineteen patients completed both imaging sessions. The carotid and peripheral arteries all have excellent short-term reproducibility of the 18F-FDG signal, with intraclass correlation coefficients all greater than 0.8 for all measures of reproducibility. Both mean and maximum TBR measurements for quantifying 18F-FDG uptake are equally reproducible. 18F-FDG uptake was significantly higher in the carotid arteries than in both iliac and femoral vessels (P < 0.001 for both). Conclusion: We found that both mean and maximum TBR in the carotid, iliac, and femoral arteries were highly reproducible. We suggest the mean TBR be used for tracking systemic arterial therapies, whereas the maximum TBR is optimal for detecting and monitoring local, plaque-based therapy.

[1]  M. Eliasziw,et al.  Statistical methodology for the concurrent assessment of interrater and intrarater reliability: using goniometric measurements as an example. , 1994, Physical therapy.

[2]  A. Freiman,et al.  Association of vascular 18F-FDG uptake with vascular calcification. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.

[4]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[5]  D. Altman,et al.  Applying the right statistics: analyses of measurement studies , 2003, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[6]  S. Libutti,et al.  Partial-Volume Correction in PET: Validation of an Iterative Postreconstruction Method with Phantom and Patient Data , 2007, Journal of Nuclear Medicine.

[7]  Martin J Graves,et al.  Identification of Culprit Lesions After Transient Ischemic Attack by Combined 18F Fluorodeoxyglucose Positron-Emission Tomography and High-Resolution Magnetic Resonance Imaging , 2005, Stroke.

[8]  Masatoshi Ishibashi,et al.  Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. , 2006, Journal of the American College of Cardiology.

[9]  C. Walker,et al.  Midterm Outcomes from the TALON Registry: Treating Peripherals with SilverHawk: Outcomes Collection , 2006, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[10]  J. Jeng,et al.  Characterization of plaques using 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[12]  V. Fuster,et al.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. , 2007, Journal of the American College of Cardiology.

[13]  Antonio Colombo,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.

[14]  Joel Karp,et al.  Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Martin J Graves,et al.  Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques contralateral to symptomatic carotid stenosis: an ultra small superparamagnetic iron oxide enhanced magnetic resonance study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[16]  R. Detrano,et al.  Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. , 2004, JAMA.

[17]  Paul Kinahan,et al.  Analytic 3D image reconstruction using all detected events , 1989 .

[18]  Zahi A Fayad,et al.  Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography , 2007, Nature Medicine.

[19]  A. Arauz,et al.  Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography Pilot study , 2007, Clinical Neurology and Neurosurgery.

[20]  Wolfgang A Weber,et al.  Monitoring cancer treatment with PET/CT: does it make a difference? , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J. Gillard,et al.  Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaque. , 2003, Circulation.

[22]  Yuji Nakamoto,et al.  Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. , 2003, Radiology.

[23]  Eric M Isselbacher,et al.  Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology. , 2004, Circulation.

[24]  M J Davies,et al.  Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.

[25]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[26]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[27]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[28]  E. Mahmud,et al.  Current treatment of peripheral arterial disease: role of percutaneous interventional therapies. , 2007, Journal of the American College of Cardiology.

[29]  K. McGraw,et al.  Forming inferences about some intraclass correlation coefficients. , 1996 .

[30]  Wolfhard Semmler,et al.  From 2D PET to 3D PET: issues of data representation and image reconstruction. , 2006, Zeitschrift fur medizinische Physik.

[31]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[32]  Keishi Kitamura,et al.  18F-FDG accumulation in atherosclerosis: use of CT and MR co-registration of thoracic and carotid arteries , 2006, European Journal of Nuclear Medicine and Molecular Imaging.